According to filings with the U.S. Securities and Exchange Commission, Melt Pharmaceuticals is raising $30,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Gregory Madison played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Melt Pharmaceuticals
Melt Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of patented non-intravenous and non-opioid sedation and analgesia medicines for short-duration medical procedures in outpatient and in-office settings. Melt’s core technology is a series of combination non-opioid sedation drug formulations that may replace or supplement current sedation modalities for more than 100 million medical procedures in the United States. Melt Pharmaceuticals is focused on the development of a novel approach to providing procedural sedation and analgesia for short-term medical procedures. Our novel and patented, rapidly dissolving sublingual tablet, provides a needle and opioid-free solution for patients and caregivers.

To learn more about Melt Pharmaceuticals, visit http://www.meltpharma.com/

Contact:
Gregory Madison, President and Chief Executive Officer
629-802-9555

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.